Helping Women Choose Appropriate Hormonal Contraception: Update on Risks, Benefits, and Indications

American Journal of Medicine

Volumn 122, Issue 6, 2009, Pages 497-506

  Spencer, Abby L ^a   Bonnema, Rachel ^b   McNamara, Megan C ^c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contraception; Contraception counseling; Contraceptive choice; Women's health

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETONOGESTREL; GESTAGEN; LOESTRIN 24; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; BLOATING; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG TREATMENT FAILURE; FAMILY PLANNING; HEADACHE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; LEUKORRHEA; MEDICAL INFORMATION; METRORRHAGIA; NAUSEA; PAIN; PATIENT COUNSELING; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SPOTTING; STROKE; VAGINAL DISCOMFORT; VENOUS THROMBOEMBOLISM;

ADULT; CLINICAL TRIALS AS TOPIC; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; COUNSELING; DESOGESTREL; EVIDENCE-BASED MEDICINE; FAMILY PLANNING SERVICES; FAMILY PRACTICE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE; OVULATION INHIBITION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RISK FACTORS; WOMEN'S HEALTH; WORLD HEALTH ORGANIZATION;

EID: 66149132231     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.016     Document Type: Review

References (53)

1. Finer S., and Henshaw K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38 2 (2006) 90-96
2. Schwartz E.B., Postlethwaite D.A., Hung Y.Y., and Armstrong M.A. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 147 (2007) 370-376
3. Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussell J., Nelson A.L., Cates W., et al. (Eds). Contraceptive Technology. 19th revised edition (2007), Ardent Media, New York NY 747-756
4. Sidney S., Petitti D.B., Soff G.A., et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 70 (2004) 3-10
5. Walker A.M. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 57 (1998) 169-181
6. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107 (2006) 1453-1472
7. Schwartz S.M., Petitti D.B., Siscovick D.S., et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 29 (1998) 2277-2284
8. MacClellan L.R., Giles W., Cole J., et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 38 (2007) 2438-2445
9. Petitti D. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 15 (2003) 1443-1450
10. World Health Organization. Low-dose combined oral contraceptives. http://www.who.int/reproductive-health/publications/mec/3_cocs.pdf Accessed August 20, 2008
11. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (2002) 2025-2032
12. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11 5 (2005) 513-525
13. Yonkers K.A., Brown C., Pearlstein T.B., et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
14. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371 (2008) 303-314
15. Schlesselman J.J. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod 12 (1997) 1851-1863
16. Nakajima S.T., Archer D.F., and Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg. Contraception 75 1 (2007) 16-22
17. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 3 (2006) 229-234
18. Archer D.F., Jensen J.T., Johnson J.V., et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 74 6 (2006) 439-445
19. Davis A.R., Kroll R., Soltes B., et al. Return to menses after continuous use of a low-dose oral contraceptive. Obstet Gynecol 107 (2006) 3S
20. Oelkers W., Foidart J.M., Dombrovicz N., et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
21. White W.B., Pitt B., Preston R.A., and Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 112 (2005) 1979-1984
22. U.S. Food and Drug Administration. Yasmin. http://www.fda.gov/Cder/consumerinfo/druginfo/yasmin.HTM Accessed August 19, 2008
23. Schlaff W.D., Lynch A.M., Hughes H.D., et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
24. Sulak P.J., Scow R.D., Preece C., et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
25. Coffee A., Kuehl T.K., Willis S.A., and Sulak P.J. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 195 (2006) 1311-1319
26. Vandever M.A., Kuehl T.J., Sulak P.J., et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 77 3 (2008) 162-170
27. Edelman A.B., Gallo M.F., Jensen J.T., et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 3 (2005) CD004695
28. Zieman M., Guillebaud J., Weisberg E., et al. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra transdermal system: the analysis of pooled data. Fertil Steril 77 2 Suppl 2 (2002) S13-S18
29. Ortho Evra Patch. http://www.fda.gov/cder/drug/infopage/orthoevra/qa2008.htm Accessed October 12, 2008
30. Toglia M.R., and Weg J.G. Venous thromboembolism during pregnancy. N Engl J Med 335 2 (1996) 108-114
31. Novak A., de la Loge C., Abetz L., and van der Meulen A. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception 67 (2003) 187-194
32. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera trademark sign): a highly effective contraceptive option with proven long-term safety. Contraception 68 (2003) 75-87
33. Haider S., and Darney P.D. Injectable contraception. Clin Obstet Gynecol 50 4 (2007) 898-906
34. Manchikanti A., Grimes D.A., Lopez L.M., and Schulz K.F. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev 2 (2007) CD006261
35. Mattson R.H., and Rebar R.W. Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 168 (1993) 2027-2032
36. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception 57 5 (1998) 315-324
37. Skegg D.C., Noonan E.A., Paul C., et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 273 10 (1995) 799-804
38. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
39. Kaunitz A.M., Miller P.D., Rice V.M., et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone aceteate: recovery following discontinuation. Contraception 74 (2006) 90-99
40. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
41. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2008) 67-76
42. World Health Organization. WHO statement on hormonal contraception and bone health (July 2005), WHO, Geneva, Switzerland. http://www.who.int/reproductive-health/family_planning/docs/hormonal_contraception_bone_health.pdf Accessed October 14, 2008
43. Hohmann H., and Crenin M.D. The contraceptive implant. Clin Obstet Gynecol 50 (2007) 907-917
44. Beerthuizen R., van Beek A., Massai R., et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15 1 (2000) 118-122
45. Graesslin O., and Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 13 Suppl 1 (2008) 4-12
46. Choice of contraceptives. Treat Guidel Med Lett 5 64 (2007) 101-108
47. Croxatto H.B., Urbancsek J., Massai R., et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum Reprod 14 (1999) 976-981
48. Makarainen L., van Beek A., Tuomivaara L., et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 69 (1998) 714-721
49. Funk S., Miller M.M., Mishell D.R., et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 71 (2005) 319-326
50. Blumenthal P.D., Gemzell-Danielsson K., and Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 13 S1 (2008) 29-36
51. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 57 (1998) 315-324
52. Conard J., Plu-Bureau G., Bahi N., et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 70 (2004) 437-441
53. Vieria C.S., Ferriani R.A., Garcia A.A., et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 22 (2007) 2196-2201